Invasive Ductal Carcinoma · What Is It, Risk Factors, Diagnosis, and More

The severity of invasive ductal carcinoma mainly depends on the tumor’s characteristics and its subtype. Tumor size is usually associated with how aggressive the carcinoma is, with larger tumors often indicating more advanced disease.  

Another important criterion is the histologic grade, measuring how abnormal cancer cells look under a microscope. Higher grades, especially grade 3, describe cells poorly differentiated, which suggests faster growth and worse outcomes. Lymph node involvement and lymphovascular invasion also increase the risk of metastasis and recurrence. In fact, biological markers play a crucial role on prognosis as tumors that are positive for estrogen (ER) and progesterone (PR) receptors tend to grow slower and respond well to hormone therapy, while HER2-positive cancers are more aggressive but treatable with targeted therapy. In contrast, triple-negative tumors (ER, PR, and HER2 negative) are often more aggressive and harder to treat. The Ki-67 proliferation index provides additional insight into how rapidly the tumor is dividing, as higher levels suggest more aggressive disease.  

Within the subtypes of IDC, tubular carcinoma is a rare, slow-growing, hormone receptor-positive subtype with an excellent prognosis. Mucinous carcinoma, seen more often in older women, is also slow-growing, mucin-rich, and typically hormone-positive with a very good outlook. Medullary carcinoma, though often triple-negative and aggressive in presentation, tends to respond well to chemotherapy and has a relatively favorable prognosis. In contrast, inflammatory carcinoma is a rare, aggressive clinical form marked by rapid onset, skin changes, and a poorer prognosis due to its advanced stage at diagnosis. 

Patient-related factors such as age, overall health, and the presence of genetic mutations like BRCA1/2 also affect both risk and treatment options. Lastly, TNM staging system (Tumor size, Node involvement, and Metastasis) is used to classify disease extent and guide therapy. 

The most common cause of invasive ductal carcinoma is DNA damage and genetic mutations of the breast tissue cells. Damage to DNA can cause changes in various genes, like BRCA1 and BRCA2, that usually control cell growth, prolong cell survival, manage cell division, and prevent unwanted cell death. If such changes occur, they can progressively result in uncontrolled cell growth, become cancerous and potentially penetrate into the stroma.  

A wide variety of genetic and environmental risk factors can lead to DNA damage and the consequent development of invasive ductal carcinoma. An individual’s sex assigned at birth is a very important risk factor, as most breast cancers occur in those who have been assigned female at birth. Additionally, advanced age increases the possibility of any malignancy, including IDC, to form. Having a personal and/or family history of breast or ovarian cancer increases the likelihood of developing IDC. In addition, a history of invasive ductal carcinoma in one breast poses a greater risk for developing a second cancerous lesion in the other breast.   

Finally, increased exposure to hormones such as estrogen also increases the risk for developing malignancies originating from the breasts, such as IDC. Factors which increase estrogen include having menarche (i.e., the first menstrual period) before 12 years of age, having the first childbirth after 30 years of age, never experiencing pregnancy, and experiencing menopause (i.e., termination of the menstrual period) after the age of 55. Similarly, exposure to administered estrogen and progesterone, for instance through various contraceptive methods (e.g., the birth control pill and intrauterine device) or through hormone replacement therapy (e.g., for postmenopausal women) poses an additional risk. 

To diagnose an invasive ductal carcinoma, a detailed medical history and physical examination, specifically of the breast and the underarm area, is necessary. Masses larger than 2 cm can usually be detected clinically. However, physical examination of the breast with no significant findings does not eliminate the possibility of an underlying invasive carcinoma. Therefore, further imaging may be required in order to reveal an IDC, which tends to grow as a dense, solid mass with calcifications. 

Diagnosis most commonly occurs during annual screening mammography as most individuals present with few other symptoms. Digital mammography usually detects masses of 1 cm or larger. However, mammography is not sensitive for invasive ductal carcinoma in young women, whose breasts tend to be more dense; in these cases breast ultrasonography can be used. Ultrasonography is also useful in assessing the consistency and size of breast lumps. Finally, magnetic resonance imaging (MRI) is ideal for high-risk individuals (e.g., BRCA mutations), evaluating the extent of known cancer, monitoring response to chemotherapy all of which require close monitoring, assessing breast implants, when planning breast conservation surgery or when mammograms are inconclusive, especially in dense breasts. It's not used for routine screening in average-risk individuals. . 

A tissue biopsy is necessary to confirm the diagnosis of IDC. The biopsy may be performed through a fine-needle aspiration (FNA), core biopsy, or excisional biopsy. 

Treatment options for invasive ductal carcinoma usually depend on the severity of each case. The basic principles of treatment are to minimize the chances of local recurrence as well as to reduce the risk of metastasis. Therefore, surgical removal of the primary lesion is the initial step towards treatment. Individuals may remove only the malignant lesion (i.e., lumpectomy), totally remove the affected breast (i.e., mastectomy) or even remove both breasts (i.e., bilateral mastectomy). Clinicians will also assess if cancerous cells have spread to other parts of the body via the lymph nodes.  The first lymph node to which cancer is likely to spread from the primary tumor is known as the sentinel lymph node. If the sentinel node is positive, meaning it contains cancerous cells, additional lymph nodes may be removed through axillary lymph node dissection; if it is negative, no further nodes are typically removed.   

In some cases, surgical treatment may be combined with radiation therapy to achieve better local control of the cancer. In more severe cases, when the cancer has spread to other parts of the body, systemic treatment options are preferred. Chemotherapy, hormonal therapies, targeted therapies (e.g., monoclonal antibodies, immunosuppressants), or a combination of these may be administered. In very advanced cases, where surgery offers small or even no improvement, palliative therapy may be offered.